Diabetes Care, Vol 23, Issue 11 1619-1629, Copyright © 2000 by American Diabetes Association

ARTICLES

The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group

OBJECTIVE: The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes. RESEARCH DESIGN AND METHODS: Eligibility requirements were age > or = 25 years, BMI > or = 24 kg/m2 (> or = 22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or < or = 6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups--intensive lifestyle modification, standard care plus metformin, and standard care plus placebo--are presented for the 3,234 participants who have been randomized. RESULTS: Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 +/- 10.7 years (mean +/- SD), and 67.7% were women. Moreover, 16% were < 40 years of age, and 20% were > or = 60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 +/- 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI > or = 30 kg/m2. Average fasting plasma glucose (6.0 +/- 0.5 mmol/l) and HbA1c (5.9 +/- 0.5%) in men were comparable with values in women (5.9 +/- 0.4 mmol/l and 5.9 +/- 0.5%, respectively). CONCLUSIONS: The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Friedman, D. Marrero, Y. Ma, R. Ackermann, K.M. V. Narayan, E. Barrett-Connor, K. Watson, W. C. Knowler, E. S. Horton, and for the Diabetes Prevention Program Research Group Value of Urinary Albumin-to-Creatinine Ratio as a Predictor of Type 2 Diabetes in Pre-Diabetic Individuals Diabetes Care, December 1, 2008; 31(12): 2344 - 2348. [Abstract] [Full Text] [PDF]

				S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]

				G. A Bray, K. A Jablonski, W. Y Fujimoto, E. Barrett-Connor, S. Haffner, R. L Hanson, J. O Hill, V. Hubbard, A. Kriska, E. Stamm, et al. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1212 - 1218. [Abstract] [Full Text] [PDF]

				K. J. Mather, T. Funahashi, Y. Matsuzawa, S. Edelstein, G. A. Bray, S. E. Kahn, J. Crandall, S. Marcovina, B. Goldstein, R. Goldberg, et al. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program Diabetes, April 1, 2008; 57(4): 980 - 986. [Abstract] [Full Text] [PDF]

				R. R. Rubin, Y. Ma, D. G. Marrero, M. Peyrot, E. L. Barrett-Connor, S. E. Kahn, S. M. Haffner, D. W. Price, W. C. Knowler, and for the Diabetes Prevention Program Research Group Elevated Depression Symptoms, Antidepressant Medicine Use, and Risk of Developing Diabetes During the Diabetes Prevention Program Diabetes Care, March 1, 2008; 31(3): 420 - 426. [Abstract] [Full Text] [PDF]

				D. G. Marrero and R. T. Ackermann Providing Long-Term Support for Lifestyle Changes: A Key to Success in Diabetes Prevention Diabetes Spectr, October 1, 2007; 20(4): 205 - 209. [Abstract] [Full Text] [PDF]

				W. H. Herman, Y. Ma, G. Uwaifo, S. Haffner, S. E. Kahn, E. S. Horton, J. M. Lachin, M. G. Montez, T. Brenneman, E. Barrett-Connor, et al. Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program Diabetes Care, October 1, 2007; 30(10): 2453 - 2457. [Abstract] [Full Text] [PDF]

				R. E. Ratner Prevention of Type 2 Diabetes in Women With Previous Gestational Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S242 - S245. [Full Text] [PDF]

				W. Y. Fujimoto, K. A. Jablonski, G. A. Bray, A. Kriska, E. Barrett-Connor, S. Haffner, R. Hanson, J. O. Hill, V. Hubbard, E. Stamm, et al. Body Size and Shape Changes and the Risk of Diabetes in the Diabetes Prevention Program Diabetes, June 1, 2007; 56(6): 1680 - 1685. [Abstract] [Full Text] [PDF]

				J. C. Florez, K. A. Jablonski, M. W. Sun, N. Bayley, S. E. Kahn, H. Shamoon, R. F. Hamman, W. C. Knowler, D. M. Nathan, D. Altshuler, et al. Effects of the Type 2 Diabetes-Associated PPARG P12A Polymorphism on Progression to Diabetes and Response to Troglitazone J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1502 - 1509. [Abstract] [Full Text] [PDF]

				J. C. Florez, K. A. Jablonski, S. E. Kahn, P. W. Franks, D. Dabelea, R. F. Hamman, W. C. Knowler, D. M. Nathan, D. Altshuler, and for the Diabetes Prevention Program Research Group Type 2 Diabetes-Associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program Diabetes, February 1, 2007; 56(2): 531 - 536. [Abstract] [Full Text] [PDF]

				R. F. Hamman, R. R. Wing, S. L. Edelstein, J. M. Lachin, G. A. Bray, L. Delahanty, M. Hoskin, A. M. Kriska, E. J. Mayer-Davis, X. Pi-Sunyer, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care, September 1, 2006; 29(9): 2102 - 2107. [Abstract] [Full Text] [PDF]

				HAPO Study Cooperative Research Group, G S. Nesbitt, M. Smye, B. Sheridan, T. R. Lappin, and E. R Trimble Integration of local and central laboratory functions in a worldwide multicentre study: Experience from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Clinical Trials, August 1, 2006; 3(4): 397 - 407. [Abstract] [PDF]

				M. R. Carnethon, R. J. Prineas, M. Temprosa, Z.-M. Zhang, G. Uwaifo, M. E. Molitch, and for the Diabetes Prevention Program Research Group The Association Among Autonomic Nervous System Function, Incident Diabetes, and Intervention Arm in the Diabetes Prevention Program Diabetes Care, April 1, 2006; 29(4): 914 - 919. [Abstract] [Full Text] [PDF]

				M C Marshall Jr Diabetes in African Americans Postgrad. Med. J., December 1, 2005; 81(962): 734 - 740. [Abstract] [Full Text] [PDF]

				D. M. Eddy, L. Schlessinger, and R. Kahn Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes Ann Intern Med, August 16, 2005; 143(4): 251 - 264. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program: Effects of Lifestyle Intervention and Metformin Diabetes, August 1, 2005; 54(8): 2404 - 2414. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group Impact of Intensive Lifestyle and Metformin Therapy on Cardiovascular Disease Risk Factors in the Diabetes Prevention Program Diabetes Care, April 1, 2005; 28(4): 888 - 894. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group* Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program Diabetes, April 1, 2005; 54(4): 1150 - 1156. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group Strategies to Identify Adults at High Risk for Type 2 Diabetes: The Diabetes Prevention Program Diabetes Care, January 1, 2005; 28(1): 138 - 144. [Abstract] [Full Text] [PDF]

				J.-L. Chiasson and R. Rabasa-Lhoret Prevention of Type 2 Diabetes: Insulin Resistance and Beta-Cell Function Diabetes, December 1, 2004; 53(suppl_3): S34 - S38. [Abstract] [Full Text] [PDF]

				L. M. Prisant Preventing Type II Diabetes Mellitus J. Clin. Pharmacol., April 1, 2004; 44(4): 406 - 413. [Abstract] [Full Text] [PDF]

				Prevention or Delay of Type 2 Diabetes Diabetes Care, January 1, 2004; 27(90001): s47 - 47. [Full Text] [PDF]

				M. E. Molitch, W. Fujimoto, R. F. Hamman, and W. C. Knowler The Diabetes Prevention Program and Its Global Implications J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S103 - 107. [Abstract] [Full Text] [PDF]

				S. M. Benjamin, R. Valdez, L. S. Geiss, D. B. Rolka, and K.M. V. Narayan Estimated Number of Adults With Prediabetes in the U.S. in 2000: Opportunities for prevention Diabetes Care, March 1, 2003; 26(3): 645 - 649. [Abstract] [Full Text] [PDF]

				D. M Nathan Preventing type 2 diabetes: what have we learned? The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S6 - S11. [Abstract] [PDF]

				The Prevention or Delay of Type 2 Diabetes Diabetes Care, January 1, 2003; 26(90001): s62 - 69. [Full Text] [PDF]

				S. H. Saydah, D. Byrd-Holt, and M. I. Harris Projected Impact of Implementing the Results of the Diabetes Prevention Program in the U.S. Population Diabetes Care, November 1, 2002; 25(11): 1940 - 1945. [Abstract] [Full Text] [PDF]

				L. M. Delahanty, J. B. Meigs, D. Hayden, D. A. Williamson, and D. M. Nathan Psychological and Behavioral Correlates of Baseline BMI in the Diabetes Prevention Program (DPP) Diabetes Care, November 1, 2002; 25(11): 1992 - 1998. [Abstract] [Full Text] [PDF]

				The Prevention or Delay of Type 2 Diabetes Clin. Diabetes, July 1, 2002; 20(3): 109 - 116. [Full Text] [PDF]

				The Prevention or Delay of Type 2 Diabetes Diabetes Spectr, July 1, 2002; 15(3): 147 - 157. [Full Text] [PDF]

				L. M. Delahanty Evidence-Based Trends for Achieving Weight Loss and Increased Physical Activity: Applications for Diabetes Prevention and Treatment Diabetes Spectr, July 1, 2002; 15(3): 183 - 189. [Abstract] [Full Text] [PDF]

				L. S. Hermann and N. Wiernsperger Impaired glucose tolerance and metformin: clinical and mechanistic aspects The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 177 - 183. [Abstract] [PDF]

				American Diabetes Association The Prevention or Delay of Type 2 Diabetes Diabetes Care, April 1, 2002; 25(4): 742 - 749. [Full Text] [PDF]

				S. Z. Yanovski and J. A. Yanovski Obesity N. Engl. J. Med., February 21, 2002; 346(8): 591 - 602. [Full Text] [PDF]

				Diabetes Prevention Program Research Group Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin N. Engl. J. Med., February 7, 2002; 346(6): 393 - 403. [Abstract] [Full Text] [PDF]

				P. A. Tataranni and C. Bogardus Changing Habits to Delay Diabetes N. Engl. J. Med., May 3, 2001; 344(18): 1390 - 1392. [Full Text] [PDF]